Choi et al. [66] studied the effects of the anti‐oncogenic EGFR inhibitors dacomitinib and canertinib on EV‐DNA cargo in lung cancer cells and found that treatment with these agents resulted in increased release of EVs harboring both EGFR and gDNA. The gene discussed is EGFR; the disease is lung cancer.